The Effect of Nasal hCT on Bone Turnover in Paget's Disease of Bone--Implications for the Treatment of Other Metabolic Bone Diseases

Reginster, Jean-Yves; JEUGMANS, Anne-Marie; Franssen, Marcelle; Sarlet, Nathalie; McIntyre, Harold David; Franchimont, Paul

doi:10.1093/rheumatology/31.1.35

Article (Scientific journals)

The Effect of Nasal hCT on Bone Turnover in Paget's Disease of Bone--Implications for the Treatment of Other Metabolic Bone Diseases

Reginster, Jean-Yves; JEUGMANS, Anne-Marie; Franssen, Marcelle et al.

1992 • In British Journal of Rheumatology, 31 (1), p. 35-9

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/125034

DOI
10.1093/rheumatology/31.1.35

PubMed
1730104

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

The Effect of Nasal hCT on Bone Turnover in Paget's Disease of Bone--Implications for the Treatment of Other Metabolic Bone Diseases.pdf

Publisher postprint (2.31 MB)

Request a copy

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Abstract :

[en] Thirty pagetic patients were treated for 6 months with a daily nasal application of 2 mg of synthetic human calcitonin (hCT). Serum alkaline phosphatases (SAP) and urinary hydroxyproline/creatinine ratio (OH/Cr), reflecting bone turnover, were significantly reduced from the first month of treatment (mean +/- SEM: SAP, -13.9 +/- 2.2%; OH/Cr, -22.2 +/- 5.8%; both P less than 0.01) and until the end of the 6-month course (mean +/- SEM: SAP, -29.7 +/- 4.6%; OH/Cr, -22.5 +/- 5.9%; both P less than 0.01). Nasal hCT was perfectly tolerated both locally and systemically. These results allow us to consider nasal hCT for long-term trials in metabolic bone diseases characterized by a relative increase of bone resorption.

Disciplines :

Rheumatology

Author, co-author :

Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie et santé publique

JEUGMANS, Anne-Marie

Franssen, Marcelle ; Centre Hospitalier Universitaire de Liège - CHU > HOSPITALISATION - UNITE STERILE ( SI -3C)

Sarlet, Nathalie ; Centre Hospitalier Universitaire de Liège - CHU > Médecine de l'appareil locomoteur

McIntyre, Harold David

Franchimont, Paul

Language :

English

Title :

The Effect of Nasal hCT on Bone Turnover in Paget's Disease of Bone--Implications for the Treatment of Other Metabolic Bone Diseases

Publication date :

January 1992

Journal title :

British Journal of Rheumatology

ISSN :

0263-7103

Publisher :

Oxford University Press, United Kingdom

Volume :

Issue :

Pages :

35-9

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 12 June 2012

Statistics

Number of views

87 (5 by ULiège)

Number of downloads

4 (3 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Meunier PJ, Coindre JM, Edouard CM, Arlot MD. Bone histomorphometry in Paget’sdisease. Quantitative and dynamic analysis of pagetic and nonpagetic bone tissues. Arthritis Rheum 1980; 23:1095-1103.
Mills BG, Singer FR. Nuclear inclusions in Paget’s disease of bone. Science 1976;194:201-2.
Rebel A, Malkani K, Basle M, Bregean Ch. Osteoclasts ultrastructure in Paget’s disease. Calcif Tissue Res 1976;20:187-9.
Raisz L, Av WY, Friedman J, Nieman I. Thyrocalcitonin and bone resorption. Am J Med 1967; 43:684-90.
Bijvoet OLM, Jansen A. Thyrocalcitonin in Paget’s disease. Lancet 1967;ii:472.
Bijvoet OLM, Sluys Veer JD, Jansen AP. Effects of calcitonin on patients with Paget’s disease, thyrotoxicosis or hypercalcaemia. Lancet 1968;i:876-81.
Greenberg PB, Doyle FH, Fisher HT, et al. Treatment of Paget’s disease of bone with synthetic human calcitonin. Am J Med 1974;56:867-71.
Gennari C, Passeri M, Chierichetti SM, Piolini M. Side effects of synthetic salmon and human calcitonin. Lancet 1983;i:594-5.
Chiba T, Taminato T, Kadowaki S, et al. Effects of [ASU l,7]-eel calcitonin on gastric somatostatin and gastrin release. Gut 1980;21:94-7.
Fink G, Gennser G, Liedholm P, Thoreil J. Comparison of plasma levels of LH-RH in men after intravenous and intranasal administration. J Endocrinol 1974;63:351-60.
Pontiroli AE, Alberetto M, Secchi A, Dossi G, Bosi I, Pozza G. Insulin given intranasally induces hypocalcaemia in normal and diabetic subjects. Br Med J 1982;284:303-6.
Pontiroli AE, Alberetto M, Pozza G. Intranasal glucagon raises blood glucose concentration in healthy volunteers. Br MedJ 1983;287:462-3.
Murlin JR, Gibb CBF, Romansky MJ, Steinhausen TB, Truax FL. Effectiveness of perioral insulin in human diabetes. Am J Physiol 1940;120:709-22.
Reginster JY, Albert A, Franchimont P. Salmon calcitonin nasal spray in Paget’s disease of bone: preliminary results in five patients. Calcif Tissue Int 1985;37:577-80.
Reginster JY, Denis D, Albert A, Franchimont P. Assessment of the biological effectiveness of nasal synthetic salmon calcitonin (SSCT) by comparison with intramuscular (i.m.) or placebo injection in normal subjects. Bone Min 1987;2:133-40.
Reginster JY, Aimer S, Gaspar S, Albert A, Deroisy R, Franchimont P. Hypocalcemie induite chez le sujet pagetique par la calcitonine salmine nasale. Effets des anticorps anti-calcitonine salmine. Rev Rhum Mai Osteo-Art 1989;56:563-6.
Nagant de Deuxchaisnes C, Devogelaer JP, Huaux JP, et al. New modes of administration of salmon calcitonin in Paget’s disease. Clin Orthop Rel Res 1987;217:56-71.
Reginster JY, Jeugmans-Huynen AM, Albert A, Denis D, Franchimont P. One year’s treatment of Paget’s disease of bone by synthetic salmon calcitonin as a nasal spray. J Bone Min Res 1988; 3:249-52.
Reginster JY, Denis D, Albert A, et al. One-year controlled randomized trial of prevention of early postmenopausal bone loss by intranasal calcitonin. Lancet 1987;ii:1481-3.
Overgaard K, Riis BJ, Christiansen C, Hawsen MA. Effect of salcatonin given intranasally on early postmenopausal bone loss. Br Med J 1989;299:477-9.
Overgaard K, Riis BJ, Christiansen C, Podenphant J, Johansen J. Nasal calcitonin for treatment of established osteoporosis. Clin Endocrinol 1989;30: 435-42.
Rico H, Hernandez ER, Diaz-Mediavilla J, Alvarez A, Martinez R, Espinos D. Treatment of multiple myeloma with nasal spray calcitonin: a histomorphometric and biochemical study. Bone Min 1990; 8:231-7.
Reginster JY, Franchimont P. Side effects of synthetic salmon calcitonin given by intranasal spray compared with intramuscular injection. Clin Exp Rheumatol 1985;3:155-7.
Meunier PJ. La maladie osseuse de Paget. Histologie quantitative et prescriptions therapeutiques. Lyon Med 1975;233:839-53.
Kanis JA, Gray RE. Long-term follow-up observations on treatment in Paget’s disease of bone. Clin Orthop Rel Res 1987;217:99-125.
Singer FR, Alderd JP, Neer AM, Krane SM, Potts JT, Bloch KJ. An evaluation of antibodies and clinical resistance to salmon calcitonin. J Clin Invest 1972;51:2331-8.
Singer FR, Fredericks RS, Minkin C. Salmon calcitonin therapy for Paget’s disease of bone. The problem of acquired resistance. Arthritis Rheum 1980;23:1148-53.
Woodhouse NJ, Mohamedally SM, Saed-Nejad F, Martin TJ. Development and significance of antibodies to salmon calcitonin in patients with Paget’s disease on long-term treatment. Br Med J 1977; 2:927-9.
Levy F, Muff R, Dotti-Sigrist S, Dambacher MA, Fisher JA. Formation of neutralizing antibodies during intranasal synthetic salmon calcitonin treatment of Paget’s disease of bone. J Clin Endocrinol Metab 1990;67:541-5.
Muff R, Dambacher MA, Perrenould A, Simon C, Fischer JA. Efficacy of intranasal human calcitonin in patients with Paget’s disease refractory to salmon calcitonin. Am J Med 1990;89:181-4.
Grauer A, Raue F, Schneider HG, Frank-Raue K, Ziegler R. In vitro detection of neutralizing antibodies after treatment of Paget’s disease of bone with nasal salmon calcitonin. J Bone Min Res 1990;5:387-91.
Hosking DJ, Denton LB, Cadge B, Martin TJ. Functional significance of antibody formation after longterm salmon calcitonin therapy. Clin Endocrinol 1979; 10:243-52.
Reginster JY, Aimer S, Gaspar S, et al. Evidence that specific antibodies do not reduce salmon calcitonin activity in vivo. Antibody, Immunoconjugates and Radiopharmaceuticals 1989;2:117-24.
Reginster JY, Gennari C, Mautalen C, et al. Influence of specific anti-salmon calcitonin antibodies on biological effectiveness of nasal salmon calcitonin in Paget’s disease of bone. Scand J Rheumatol 1990; 19:83-6.
Bouiz’ar Z, Rostene WH, Milhaud G. Down-regulation of rat kidney calcitonin receptors by salmon calcitonin infusion evidenced by autoradiography. Proc NatlAcad Sci USA 1987;84:5125-8.
Rojanasathit S, Rosenberg E, Haddad JG. Paget’s bone disease: response to human calcitonin in patients resistant to salmon calcitonin. Lancet 1974;ii:1412-15.
Altman R, Collins-Yudishas B. Synthetic human calcitonin in refractory Paget’s disease of bone. Arch Intern Med 1987;147:1305-8.
Pontiroli AE, Alberetto M, Pozza G. Intranasal calcitonin and plasma calcium concentration in normal subjects. Br Med J 1985;290:1390-1.
Ziegler R, Holz G, Rave F, Streibl W. Nasal application of human calcitonin in Paget’s disease of bone. In: Maclntyre I, Szelke M, eds. Moleculaet al.ndocrinology. Amsterdam, New York, Oxford: Elsevier, 1979: 293-300.
Trayser KA, Seligson D. A new kinetic method for enzyme analysis suitable for automation. Clin Chem 1969;15:452.
Epstein S, Owen G. Paget’s disease of bone treated with human synthetic calcitonin. South Afr Med J 1977;51:133-7.
Guttmann S. Chemistry and structure-activity relationship of natural and synthetic calcitonins. In: Pecile A, ed. Calcitonin 1980: chemistry, physiology, pharmacology and clinical aspects. Amsterdam, Princeton, Oxford: Excerpta Medica Publ, 1981: 11-24.
Altman RD. Synthetic salmon calcitonin (NCT) by nasal spray in Paget’s disease of bone. J Bone Min Res 1990;5:204(a).
Singer FR, Ahrne-Collier I. Salmon calcitonin therapy; antibodies and clinical resistance in Paget’s disease of bone. Molec Endocrinol 1977;1:207-13.
Altman R, Johnston CC, Khairi MRA, Wellman H, Serafini AN, Sonkey RR. Influence of disodium etidronate on clinical and laboratory manifestations of Paget’s disease of bone. N Engl J Med 1973;289:1379-84.
Frijlink WB, te Velde J, Bijvoet OLM, Heynen G. Treatment of Paget’s disease of bone with (3-amino-l-hydroxypropylidene-1,1-bisphosphonate) (APD). Lancet 1979;i:799-803.
Reginster JY, Jeugmans-Huynen AM, Albert A, et al. Biological and clinical assessment of a new bisphosphonate, (chloro-4 phenyl) thiomethylene bisphosphonate, in the treatment of Paget’s disease of bone. Bone 1989;9:349-54.
Meunier PJ, Chapuy MC, Alexandre C, et al. Effects of disodium dichloromethylene diphosphonate (CL2 MDP) on Paget’s disease of bone. Lancet 1979;ii:489.